Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Antiemetics × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 3 Plasma cell 2 Genitourinary 2 Gastrointestinal 2 Endocrine 2 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 NET 1 CNS 1

Conditions

Advanced Solid Tumors 1

Interventions

Cisplatin 145 pembrolizumab 129 Carboplatin 123 Injections 108 Paclitaxel 97 Pemetrexed 96 Gemcitabine 84 Irinotecan 75 Cyclophosphamide 71 Nivolumab 70 Docetaxel 68 Bevacizumab 58 Oxaliplatin 50 Fluorouracil 49 atezolizumab 46 Capecitabine 46 Leucovorin 42 Etoposide 42 tislelizumab 40 toripalimab 36 fludarabine 31 Drug Therapy 30 Topotecan 29 Ipilimumab 29 durvalumab 28 Vincristine 27 Early Intervention, Educational 27 Radiotherapy 26 Filgrastim 25 spartalizumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06242691 2026-03-06

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡